[Clinical evaluation of a new carbapenem antibiotic, biapenem (L-627), in the pediatric field].
Biapenem (L-627) was evaluated for its safety and efficacy in 27 children with various bacterial infections. L-627 was effective in cases with osteomyelitis due to Staphylococcus aureus, pneumonia and purulent meningitis due to penicillin-resistant Streptococcus pneumoniae, and urinary tract infections due to Enterococcus faecalis, Escherichia coli, or Pseudomonas aeruginosa. However, L-627 failed to produce good responses in 2 of 7 cases of Haemophilus influenzae infections. Pharmacokinetic parameters of 30-minutes infusion of 12 mg/kg were as follows: Cmax 29-46 micrograms/ml, T 1/2 0.68-0.94 hr. Adverse reactions were minimal. These data suggest that L-627 is safe in children, and is valuable especially for treatment of infections in immunocompromised hosts and infections due to multiply resistant bacteria.
Meguro
H
H
Department of Pediatrics, Teikyo University Ichihara Hospital.
Fujii
R
R
Terashima
I
I
Ishikawa
N
N
Kuroki
H
H
Niimi
H
H
Nakamura
A
A
Ohshima
H
H
Kurosaki
T
T
Toba
T
T
D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D016920:Meningitis, Bacterial / Q000188:drug therapy / Q000378:metabolism; D010019:Osteomyelitis / Q000188:drug therapy / Q000378:metabolism; D013845:Thienamycins / Q000493:pharmacokinetics / Q000627:therapeutic use*
D013845:Thienamycins; C065257:biapenem